US · Healthcare · Biotechnology
EPS came in at -0.46 against a street estimate of -0.66 — a beat of 30.3%.
Analysts rate Zai Lab Ltd a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $33.14.
CONFIDENT Zai Lab pivoting to global biopharmaceutical company with first US submission expected 2027. China business stabilizing with 11% sequential growth; three registrational programs underway by year-end across oncology. Q2 2026 Company transitioning from China-focused to global biopharmaceutical player. China business stabilizing as foundation for 2027 growth; global pipeline emerging as primary growth driver. Analysts probed ESMO efficacy benchmarks (80% ORR target), competitive AD differentiation (YTE dosing advantage, market size), and mechanism-of-action synergies (DLL3 dual targeting). Management emphasized speed, mechanistic rationale, and data timing without conceding market share risks. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| RTW INVESTMENTS, LLC | 5.86% |
| TCG Crossover Management, LLC | 5.47% |
| RA Capital Management, LLC | 5.08% |
| Frazier Life Sciences Management, L.P. | 1.69% |
| BAMCO Inc | 1.48% |
| ADAR1 Capital Management LLC | 1.27% |
| Two Sigma Investments LLC | 1.16% |
| Citadel Advisors Llc | 1.14% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ZAI LAB LIMITED – Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash & Equivalents: $607.5 million (June 30, 2026) vs $679.6 million (Dec 31, 2025) – | 2026-08-06 |
| Results announced · Q3 2026 ZAI LAB LIMITED – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenues: $106.3 million in Q2 2026 vs. $110.0 million in Q2 2025 (down 3%) • P | 2026-08-06 |
| Shareholder vote results · Q2 2026 ZAI LAB LIMITED – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting held June 17, 2026 • 550,281,867 ordinary shares represented (more than | 2026-06-17 |
| Board / officer change · Q2 2026 ZAI LAB LIMITED – FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: May 18, 2026 • Company: Zai Lab Limited (Nasdaq: ZLAB; Hong Kong: 9688) • Headqua | 2026-05-21 |
| Quarterly report · Q1 2026 ZAI LAB LIMITED – Q1 2026 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Cash Position: $651.3 million as of March 31, 2026 (down from $679.6 | 2026-05-07 |
| Results announced · Q2 2026 ZAI LAB LIMITED – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenues: $99.6 million in Q1 2026 vs. $106.5 million in Q1 2025 (down 6% year- | 2026-05-07 |
| Proxy statement · Q2 2026 ZAI LAB LIMITED — 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Samantha (Ying) Du, Founder/CEO/Board Chair: Total compensation figure not sp | 2026-04-28 |
| Annual report FY2025 ZAI LAB LIMITED - 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Public company incorporated in Cayman Islands, listed on NASDAQ (ticker: ZLAB) and H | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zai Lab Ltd — free to start.
Google PlayApp StoreData updated 2026-09-18.